iSAM Funds UK Ltd Takes Position in Abbott Laboratories $ABT

Key Points

• iSAM Funds UK Ltd initiated a position in Abbott Laboratories during the second quarter, buying 14,800 shares valued at approximately $1.34 million. Institutional investors collectively own 75.18% of ABT’s outstanding stock.
• Analysts maintain a generally positive view, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $119.50, despite some recent target-price reductions.
• Abbott exceeded quarterly earnings and revenue expectations, reporting $1.31 in adjusted EPS and $12.59 billion in revenue, while declaring a quarterly dividend of $0.63 per share, equivalent to a 2.3% annualized yield.

iSAM Funds UK Ltd bought a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 14,800 shares of the healthcare product maker's stock, valued at approximately $1,343,000. Abbott Laboratories comprises 1.0% of iSAM Funds UK Ltd's holdings, making the stock its 21st biggest position.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ABT. Nia Impact Advisors LLC raised its position in shares of Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker's stock valued at $504,000 after purchasing an additional 79 shares during the last quarter. Riggs Asset Managment Co. Inc. grew its position in Abbott Laboratories by 9.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker's stock worth $140,000 after purchasing an additional 88 shares during the last quarter. Eley Financial Management Inc increased its stake in Abbott Laboratories by 0.9% during the 4th quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker's stock valued at $1,355,000 after purchasing an additional 92 shares in the last quarter. Copley Financial Group Inc. raised its holdings in shares of Abbott Laboratories by 2.1% in the fourth quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker's stock worth $556,000 after buying an additional 93 shares during the last quarter. Finally, Kelleher Financial Advisors raised its holdings in shares of Abbott Laboratories by 2.9% in the third quarter. Kelleher Financial Advisors now owns 3,301 shares of the healthcare product maker's stock worth $442,000 after buying an additional 93 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ABT shares. Bank of America cut their target price on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Wolfe Research upgraded Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price target on the stock in a research note on Thursday, August 13th. UBS Group cut their price objective on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, July 28th. Weiss Ratings raised Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 6th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $119.50.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $108.29 on Monday. The company has a market capitalization of $187.38 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The company's fifty day moving average price is $104.43 and its 200 day moving average price is $100.03. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm's revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories's dividend payout ratio is presently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source